Press release
Pulmonary Hypertension Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Treatment Outlook, and Key Companies | Arena Pharmaceuticals, United Therap
"Pulmonary Hypertension Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pulmonary Hypertension Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Pulmonary Hypertension Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Pulmonary Hypertension Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Hypertension treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Pulmonary Hypertension market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Learn More about the Clinical and Commercial Development Activities in the Pulmonary Hypertension Therapeutics Domain:
https://www.delveinsight.com/report-store/pulmonary-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Pulmonary Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
Molecule Type
Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/pulmonary-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Pulmonary Hypertension Therapeutics Analysis
There are approx. 80+ key companies developing therapies for Pulmonary Hypertension. Currently, Akaza Bioscience is leading the therapeutics market with its Pulmonary Hypertension drug candidates in the most advanced stage of clinical development.
Leading Companies in the Pulmonary Hypertension Therapeutics Market Include:
Aadi Biosciences, Acceleron Pharma, Aerami Therapeutics, Aerovate Therapeutics, Altavant Sciences, Apeiron Biologics, Aqualung Therapeutics, AstraZeneca, Attgeno, ATXA Therapeutics, Bellerophon Therapeutics, Bial - Portela C S.A., Camurus, Celon Pharma, Cereno Scientific, Claritas Pharmaceuticals, Cumberland Pharmaceuticals, Dong-A ST/Mezzion, Gmax Biopharma, Gossamer Bio, Merck Sharp & Dohme Corp., Northern Therapeutics, Pfizer, Pharmosa BioPharm, PhaseBio Pharmaceuticals, Pulmokine, Reata Pharmaceuticals, Recursion Pharmaceuticals, Respira Therapeutics, Resverlogix, Reviva Biopharmaceuticals, Rho Federal Systems Division, Inc., Roche, SystImmune, United Therapeutics Corporation, Vigonvita Life Sciences, VIVUS, and others.
Pulmonary Hypertension Emerging and Marketed Drugs Covered in the Report Include:
• Ralinepag: Arena Pharmaceuticals/United Therapeutics
• Sotatercept: Acceleron Pharma
• Zamicastat: Bial - Portela C S.A.
• Tocilizumab: Roche
• AER-901: Aerami Therapeutics
• ABI-009: Aadi Biosciences
And Many More
Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/pulmonary-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Pulmonary Hypertension Current Treatment Patterns
4. Pulmonary Hypertension - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Pulmonary Hypertension Late-Stage Products (Phase-III)
7. Pulmonary Hypertension Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pulmonary Hypertension Discontinued Products
13. Pulmonary Hypertension Product Profiles
14. Pulmonary Hypertension Key Companies
15. Pulmonary Hypertension Key Products
16. Dormant and Discontinued Products
17. Pulmonary Hypertension Unmet Needs
18. Pulmonary Hypertension Future Perspectives
19. Pulmonary Hypertension Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/pulmonary-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Other Trending Healthcare Reports by DelveInsight
Insulin Glargine Biosimilar
https://www.delveinsight.com/report-store/insulin-glargine-biosimilar-insight
HDAC Inhibitors Market
https://www.delveinsight.com/report-store/hdac-inhibitors-market
Vutrisiran Market
https://www.delveinsight.com/report-store/vutrisiran-market
mRNA Vaccine and Therapeutics Market
https://www.delveinsight.com/report-store/mrna-vaccine-and-therapeutics-market
Asthma Diagnostic Devices Market
https://www.delveinsight.com/report-store/asthma-diagnostic-devices-market
Holter Monitor Market
https://www.delveinsight.com/report-store/holter-monitor-market
Total Knee Arthroplasty Market
https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Sacral Nerve Stimulator Devices Market
https://www.delveinsight.com/report-store/sacral-nerve-stimulator-devices-market
Cardiac Monitoring System Market
https://www.delveinsight.com/report-store/cardiac-monitoring-system-market
Implantable Cardioverter Defibrillators (ICDs) Market
https://www.delveinsight.com/report-store/implantable-cardioverter-defibrillators-icds-market
Spirometers Market
https://www.delveinsight.com/report-store/spirometers-market
Breast Pumps Market
https://www.delveinsight.com/report-store/breast-pumps-market
Dental Lasers Market
https://www.delveinsight.com/report-store/dental-lasers-market
Point of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
Negative Pressure Wound Therapy Systems Market
https://www.delveinsight.com/report-store/negative-pressure-wound-therapy-systems-market
India Healthcare Outlook Report
https://www.delveinsight.com/report-store/india-healthcare-outlook-report
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Hypertension Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Treatment Outlook, and Key Companies | Arena Pharmaceuticals, United Therap here
News-ID: 3053190 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Pulmonary
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Embolism Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Pulmonary Embolism Market is exhibited at USD 1.59 billion in 2023 and is projected to surpass USD 3.15 billion in 2028, anticipated to grow at a CAGR of 8.4% from 2023 to 2028.
The rapid increase in the prevalence of cancer, increasing investment for healthcare infrastructure and rising research and development activities, high disposable income, rising demand…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
